ALX Oncology Holdings, Inc.

As of May 17, 2021, ALX Oncology Holdings, Inc. is considered overvalued due to significant operational losses and negative return metrics, with a valuation grade that has shifted from risky to does not qualify, underperforming the S&P 500 with a year-to-date return of -72.47%.

As of June 2, 2025, ALX Oncology Holdings, Inc. shows a mildly bearish trend due to daily moving averages, despite some bullish signals from weekly indicators, while overall performance remains weak compared to the S&P 500.

As of March 2022, the management team of ALX Oncology Holdings, Inc. includes Dr. Corey Goodman as Executive Chairman and Dr. Jaume Pons as President and CEO. The Board of Directors also features independent members Ms. Rekha Hemrajani, Mr. Jason Lettmann, Mr. Jack Nielsen, and Dr. Graham Walmsley.

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company developing therapies targeting the CD47 checkpoint pathway to combat cancer. It has a market capitalization of $26.47 million and reported a net profit loss of $31 million as of March 2025.

As of Jun 18, ALX Oncology Holdings, Inc. has a market capitalization of 26.47 million, with net sales of 0.00 million and a net profit of -130.02 million. The balance sheet shows shareholder's funds of 113.62 million and total assets of 147.78 million.